|Bid||48.80 x 900|
|Ask||49.30 x 1000|
|Day's range||47.89 - 53.50|
|52-week range||41.33 - 277.80|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
NEW YORK, December 03, 2021--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline.
SAN DIEGO, December 01, 2021--Novavax, Inc. (NVAX) Misled Shareholders Regarding Approval of its COVID Vaccine
SAN DIEGO, November 27, 2021--The suit alleges defendants issued false statements concerning Novavax business and prospects, resulting in its stock trading at inflated prices.